| ［1］ |
郑荣寿，陈茹，韩冰峰，等. 2022年中国恶性肿瘤流行情况分析［J］. 中华肿瘤杂志，2024，46（3）: 221-231.
|
| ［2］ |
Wang Q，Luo W，Li Y，et al. Tumor Compression of the Hepatic or Portal Vein Predicts the Presence of Microvascular Invasion and Satellite Nodules in Hepatocellular Carcinoma: A Retrospective Study［J］. Journal of hepatocellular carcinoma，2025，12: 2055-2067.
|
| ［3］ |
Nevola R，Ruocco R，Criscuolo L，et al. Predictors of early and late hepatocellular carcinoma recurrence［J］. World journal of gastroenterology，2023，29（8）: 1243-1260.
|
| ［4］ |
Zhang J，Guo L，Zeng C，et al. Time to recurrence and BCLC stage at recurrence as critical variables in guiding treatment decisions for early-recurrent hepatocellular carcinoma after liver resection［J］. Frontiers in oncology，2025，15: 1672696.
|
| ［5］ |
Zhu Y，Gu L，Chen T，et al. Factors influencing early recurrence of hepatocellular carcinoma after curative resection［J］. Journal of International Medical Research，2020，48（8）: 300060520945552.
|
| ［6］ |
Zhou L，Rui J，Zhou W，et al. Edmondson-Steiner grade: A crucial predictor of recurrence and survival in hepatocellular carcinoma without microvascular invasio［J］. Pathology-Research and Practice，2017，213（7）: 824-830.
|
| ［7］ |
Zheng G，Zheng M，Hu P，et al. Lasso-Based Nomogram for Predicting Early Recurrence Following Radical Resection in Hepatocellular Carcinoma［J］. Journal of hepatocellular carcinoma，2025，12: 539-552.
|
| ［8］ |
Jung S，Kim JM，Choi G，et al. Characteristics of Early Recurrence After Curative Liver Resection for Solitary Hepatocellular Carcinoma［J］. Journal of Gastrointestinal Surgery，2019，23（2）: 304-311.
|
| ［9］ |
Lee HA，Lee Y，Kim BK，et al. Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma［J］. Gut and Liver，2021，15（3）: 420-429.
|
| ［10］ |
杨浩，杨连粤. 肝癌术后复发转移相关因素研究进展［J］. 中国实用外科杂志，2012，32（10）: 876.
|
| ［11］ |
Wang M，Li C，Liang L，et al. Early and Late Recurrence of Hepatitis B Virus-Associated Hepatocellular Carcinoma［J］. The Oncologist，2020，25（10）: e1541-e1551.
|
| ［12］ |
Yoon JH，Choi SK，Cho SB，et al. Early extrahepatic recurrence as a pivotal factor for survival after hepatocellular carcinoma resection: A 15-year observational study［J］. World journal of gastroenterology: WJG，2022，28（36）: 5351-5363.
|
| ［13］ |
Yan M，Zhang X，Zhang B，et al. Deep learning nomogram based on Gd-EOB-DTPA MRI for predicting early recurrence in hepatocellular carcinoma after hepatectomy［J］. European Radiology，2023，33（7）: 4949-4961.
|
| ［14］ |
Liu Y，Yong C，Lin C，et al. Six months as a cutoff time point to define early recurrence after liver resection of hepatocellular carcinoma based on post-recurrence survival［J］. Updates in Surgery，2021，73（2）: 399-409.
|
| ［15］ |
Yan W，Li C，Yao L，et al. Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study［J］. Hepatobiliary Surgery and Nutrition，2023，12（2）: 155-168.
|
| ［16］ |
Zhou K，Sun Y，Cheng J，et al. Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma［J］. eBio Medicine，2020，62: 103107.
|
| ［17］ |
Liu J，Zhuang G，Bai S，et al. The Comparison of Surgical Margins and Type of Hepatic Resection for Hepatocellular Carcinoma With Microvascular Invasion［J］. The Oncologist，2023，28（11）: e1043-e1051.
|
| ［18］ |
Xing H，Zhang W，Cescon M，et al. Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study［J］. HPB，2020，22（5）: 677-689.
|
| ［19］ |
Wang W，Guo Y，Zhong J，et al. The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma［J］. Scientific Reports，2021，11（1）: 2415.
|
| ［20］ |
Law J，Shao H，DasGupta R，et al. Developing risk stratification strategies and biomarkers for recurrent hepatocellular carcinoma［J］. Clinical and translational medicine，2025，15（8）: e70410.
|
| ［21］ |
Papatheodoridi M，Tampaki M，Lok AS，et al. Risk of HBV reactivation during therapies for HCC: A systematic review［J］. Hepatology，2022，75（5）: 1257-1274.
|
| ［22］ |
《原发性肝癌诊疗指南（2024年版）》编写专家委员会. 原发性肝癌诊疗指南（2024年版）［J］. 中国临床医学，2024，31（2）: 277-334.
|
| ［23］ |
李新省，张丽敏，王烨，等. 切缘宽度对原发性肝癌合并微血管侵犯患者并发症及预后的影响［J/OL］. 中华普外科手术学杂志（电子版），2022，16（6）: 622-626.
|
| ［24］ |
Bai S，Yang P，Liu J，et al. Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE［J］. The Oncologist，2023，28（8）: e633-e644.
|
| ［25］ |
Tai Y H，Wu HL，Mandell MS，et al. The association of allogeneic blood transfusion and the recurrence of hepatic cancer after surgical resection［J］. Anaesthesia，2020，75（4）: 464-471.
|
| ［26］ |
Nakayama H，Okamura Y，Higaki T，et al. Effect of blood product transfusion on the prognosis of patients undergoing hepatectomy for hepatocellular carcinoma: a propensity score matching analysis［J］. Journal of gastroenterology，2023，58（2）: 171-181.
|
| ［27］ |
Katz SC，Shia J，Liau KH，et al. Operative Blood Loss Independently Predicts Recurrence and Survival After Resection of Hepatocellular Carcinoma［J］. Annals of Surgery，2009，249（4）: 617-623.
|
| ［28］ |
Altaf A，Akabane M，Khalil M，et al. Impact of intraoperative blood loss in postoperative morbidity after liver resection for primary and secondary liver cancer［J］. HPB: the official journal of the International Hepato Pancreato Biliary Association，2025，27（5）: 660-669.
|
| ［29］ |
Pan Y，Wang J，Lu X，et al. Intention to control low central venous pressure reduced blood loss during laparoscopic hepatectomy: A double-blind randomized clinical trial［J］. Surgery，2020，167（6）: 933-941.
|
| ［30］ |
Xiao L，Huang P，Wu K，et al. Effect of infrahepatic inferior vena cava partial clamping on central venous pressure and intraoperative blood loss during laparoscopic hepatectomy［J］. Surgical Endoscopy，2021，35（6）: 2773-2780.
|
| ［31］ |
陆朝阳，金也，孙备. 腹腔镜解剖性肝切除的发展［J/OL］. 中华普外科手术学杂志（电子版），2024，18（4）: 363-366.
|
| ［32］ |
Kaibori M，Kon M，Kitawaki T，et al. Comparison of anatomic and non‐anatomic hepatic resection for hepatocellular carcinoma［J］. Journal of Hepato-Biliary-Pancreatic Sciences，2017，24（11）: 616-626.
|
| ［33］ |
Jiao S，Li G，Zhang D，et al. Anatomic versus non-anatomic resection for hepatocellular carcinoma，do we have an answer？A meta-analysis［J］. International Journal of Surgery，2020，80: 243-255.
|
| ［34］ |
雷彩宁，李子汉，李小飞，等. 解剖性切除与非解剖性切除治疗肝细胞癌患者疗效的Meta分析［J］. 中国普通外科杂志，2021，30（2）: 195-210.
|
| ［35］ |
Meng X，Chen F，Tang T，et al. Anatomical resection is associated with reduced early recurrences in HCC: A machine learning analysis［J］. JHEP reports: innovation in hepatology，2025，7（11）: 101565.
|
| ［36］ |
Kim JM，Yi N，Kwon CHD，et al. Early disseminated recurrence after liver resection in solitary hepatocellular carcinoma［J］. Annals of Surgical Treatment and Research，2018，94（3）: 129.
|
| ［37］ |
Fang T，Long G，Mi X，et al. Splenic Volume，an Easy-To-Use Predictor of HCC Late Recurrence for HCC Patients After Hepatectomy［J］. Frontiers in Oncology，2022，12: 876668.
|
| ［38］ |
Du Z，Liu X，Wei X，et al. Quantitative proteomics identifies a plasma multi-protein model for detection of hepatocellular carcinoma［J］. Scientific Reports，2020，10（1）: 15552.
|
| ［39］ |
Liu Y，Jiang W，Li X，et al. The Diagnostic Performance of AFP，AFP-L3，DCP，CA199，and Their Combination for Primary Liver Cancer［J］. Journal of hepatocellular carcinoma，2025，12: 513-526.
|
| ［40］ |
Zhu W，Wang W，Zheng W，et al. Diagnostic performance of PIVKA-Ⅱ in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study［J］. Scientific reports，2024，14（1）: 8416.
|
| ［41］ |
Wang B，Tan Q，Gao X，et al. Elevated PIVKA-Ⅱ is associated with early recurrence and poor prognosis in BCLC 0-A hepatocellular carcinomas［J］. Asian Pac J Cancer Prev，2014，15（16）: 6673-6678.
|
| ［42］ |
Hong YM，Cho M，Yoon KT，et al. Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma［J］. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine，2017，39（10）: 1010428317720863.
|
| ［43］ |
Kladney RD，Bulla GA，Guo L，et al. GP73，a novel Golgi-localized protein upregulated by viral infection［J］. Gene，2000，249（1-2）: 53-65.
|
| ［44］ |
Schwegler EE，Cazares L，Steel LF，et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma［J］. Hepatology（Baltimore，Md.），2005，41（3）: 634-642.
|
| ［45］ |
Cao K，Wu L，Wang X，et al. Risk Factors for Early Recurrence After Radical Resection of Hepatocellular Carcinoma Based on Preoperative Contrast-Enhanced Ultrasound and Clinical Features［J］. Technology in cancer research &treatment，2024，23: 15330338241281327.
|
| ［46］ |
Ye Q，Zhu W，Zhang J，et al. GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma Metastasis［J］. Cancer cell，2016，30（3）: 444-458.
|
| ［47］ |
Mao Y，Yang H，Xu H，et al. Golgi protein 73（GOLPH2）is a valuable serum marker for hepatocellular carcinoma［J］. Gut，2010，59（12）: 1687-1693.
|
| ［48］ |
Zhou J，Yu L，Gao X，et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma［J］. Journal of clinical oncology: official journal of the American Society of Clinical Oncology，2011，29（36）: 4781-4788.
|
| ［49］ |
Huang A，Guo D，Wang Y，et al. Plasma MicroRNA Panel Predicts Early Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation［J］. Journal of Cancer，2021，12（23）: 7190-7200.
|
| ［50］ |
Zhou C，Zhou H，Zhang X，et al. Postoperative Serum Osteopontin Level is a Novel Monitor for Treatment Response and Tumor Recurrence after Resection of Hepatitis B–related Hepatocellular Carcinoma［J］. Annals of Surgical Oncology，2013，20（3）: 929-937.
|
| ［51］ |
Yang G，Fan J，Xu Y，et al. Osteopontin Combined with CD44，a Novel Prognostic Biomarker for Patients with Hepatocellular Carcinoma Undergoing Curative Resection［J］. The Oncologist，2008，13（11）: 1155-1165.
|
| ［52］ |
Simão A，Madaleno J，Silva N，et al. Plasma osteopontin is a biomarker for the severity of alcoholic liver cirrhosis，not for hepatocellular carcinoma screening［J］. BMC Gastroenterology，2015，15（1）: 73.
|
| ［53］ |
Kalinich M，Bhan I，Kwan TT，et al. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma［J］. Proceedings of the National Academy of Sciences of the United States of America，2017，114（5）: 1123-1128.
|
| ［54］ |
Ren Q，Li S，Zhong G，et al. Non-Invasive Tumor-Naïve Minimal Residual Disease Detection of Liver Cancer by Incorporating Circulating Tumor DNA Features and Alpha-Fetoprotein: A Prospective Study［J］. Cancer medicine，2024，13（24）: e70511.
|
| ［55］ |
Ren T，Hou X，Zhang X，et al. Validation of combined AFP，AFP-L3，and PIVKA Ⅱ for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients［J］. Heliyon，2023，9（11）: e21906.
|
| ［56］ |
Sun Y，Wu L，Zhong Y，et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma［J］. Cell，2021，184（2）: 404-421.
|
| ［57］ |
Yang M，Song X，Zhang F，et al. Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse［J］. Hepatology（Baltimore，Md.），2025，81（5）: 1452-1467.
|
| ［58］ |
Jia G，He P，Dai T，et al. Spatial immune scoring system predicts hepatocellular carcinoma recurrence［J］. Nature，2025，640（8060）: 1031-1041.
|